Your shopping cart is currently empty

VEGFR-2-IN-62 (Compound 3f) is a potent inhibitor of VEGFR-2, with an IC50 value of 0.0557 μM. It inhibits cell proliferation and induces apoptosis (Apoptosis), making it useful for cancer research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | VEGFR-2-IN-62 (Compound 3f) is a potent inhibitor of VEGFR-2, with an IC50 value of 0.0557 μM. It inhibits cell proliferation and induces apoptosis (Apoptosis), making it useful for cancer research. |
| Targets&IC50 | VEGFR2:0.0557 μM |
| In vitro | VEGFR-2-IN-62 (Compound 3f) at 0.08 μM for 24 hours induces apoptosis in MCF-7 cells, significantly increasing Bax levels while decreasing Bcl2 levels, thereby greatly enhancing the Bax/Bcl2 ratio [1]. It exhibits antiproliferative activity against HepG2, MCF-7, and VERO human tumor cell lines with IC50 values of 0.17, 0.08, and 1.98 μM, respectively [1]. Additionally, VEGFR-2-IN-62 at 2.3 μM for 24 hours causes cell cycle arrest at the G2-M phase in MCF-7 cells [1]. |
| Molecular Weight | 467.906 |
| Formula | C26H18ClN5O2 |
| Smiles | C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)C(=O)N/N=C/C4=CC=CO4)C5=CC=C(C=C5)Cl |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.